Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention

BOTHELL, Wash., March 06, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data for eptinezumab (formerly ALD403), which is in clinical development for the prevention of migraine, will be presented at the upcoming 69^th Annual American Academy of Neurology meeting on April 22-28, 2017 in Boston.

• Platform presentation: Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine
  
  Session: S52, Headache: Clinical Trials and Disease Burden 
  Date: Friday, April 28, 2017
  Presenter: Dr. David Dodick
  Time: 1:24 p.m.
  Location:  Boston Convention and Exhibition Center
  
  

• Poster presentation: Rational Design of a Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine
  
  Poster: #155
  Date: Monday, April 24
  Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT
  Location:  Boston Convention and Exhibition Center, Poster Session II
  
  

• Poster presentation: 75% Responder Rates Provide Improvement in HIT-6 Scores from Week 4 Through 12 Following a Single Infusion of ALD403, or Placebo
  
  Poster: #165 
  Date: Monday, April 24 
  Poster Q & A Session: 5:30 p.m. – 7:00 p.m. EDT 
  Location: Boston Convention and Exhibition Center, Poster Session II

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:
David Schull or Victoria Meissner
Russo Partners, LLC
(212) 845-4271
(646) 942-5627
[email protected]
[email protected]

Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals Inc.
(425) 408-8032
[email protected]